-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Evolving the Standard of Care: Rethinking the Treatment Paradigm for Iron Deficiency Anemia

Sponsor: an independant educational grant from Pharmacosmos Therapeutics, Inc.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Anemias, Diseases, Non-Biological, Therapies, Adverse Events, iron deficiency, pharmacology
Friday, December 4, 2020: 3:00 PM-6:00 PM
Chair:
Carlo Brugnara, MD, Harvard Medical School, Boston Children's Hospital
Disclosures:
Brugnara: Sysmex America Inc.: Consultancy; American Journal of Hematology: Other.
Speakers:
Michael Auerbach, MD, FACP, Auerbach Hematology and Oncology and Myles Wolf, MD, MMsc, Duke University School of Medicine
Disclosures:
Auerbach: AMAG: Research Funding; Sysmex: Research Funding. Wolf: Akebia: Consultancy, Honoraria; Pharmacosmos: Consultancy, Honoraria; Bayer: Consultancy; AstraZeneca: Consultancy, Honoraria; Ardelyx: Consultancy, Honoraria; Amag: Consultancy, Honoraria.
Iron deficiency anemia (IDA) continues to be a significant public health burden leading to a number of adverse health outcomes. Although oral iron is traditionally viewed as fist-line therapy, this is largely due to perceived safety issues with older intravenous (IV) iron formulations. Newer IV iron formulations show comparable efficacy and safety to oral agents, which may present a more convenient and cost-effective treatment option for the management of IDA.

Join our panel of top experts for an interactive, virtual, CME-certified symposium providing up-to-date information for the treatment of iron deficiency anemia, including the pathophysiology of IDA in order to accurately identify and diagnose patients at increased risk. The efficacy and safety of different iron replacement formulations will also be discussed to inform the selection of the appropriate therapy to optimize the management of patients.

See more of: Satellite Symposia